Platelet rich plasma, stromal vascular fraction and autologous conditioned serum in treatment of knee osteoarthritis

Fotouhi, Ali; Maleki, Arash; Dolati, Sanam; Aghebati‐Maleki, Ali

doi:10.1016/j.biopha.2018.05.019

Cited by 61 publications

(48 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The efficacy of blood products especially with focus on knee OA has been investigated in several clinical trials and reviewed extensively. In general, blood products are well tolerated and provide reduction of pain and inflammation, as well as increased range of motion (Fotouhi et al, 2018;Tassara et al, 2018;Zarringam et al, 2018;Gato-Calvo et al, 2019). Autologous blood products are subfractions of whole blood drawn from a patient and are produced directly in the operation theater or for ambulatory treatment prior to application.…”

Section: Introductionmentioning

confidence: 99%

Characterization and Chondroprotective Effects of Extracellular Vesicles From Plasma- and Serum-Based Autologous Blood-Derived Products for Osteoarthritis Therapy

Otahal

Kramer

Kuten

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Autologous blood products gain increasing interest in the field of regenerative medicine as well as in orthopedics, aesthetic surgery, and cosmetics. Currently, citrate-anticoagulated platelet-rich plasma (CPRP) preparations are often applied in osteoarthritis (OA), but more physiological and cell-free alternatives such as hyperacute serum (hypACT) are under development. Besides growth factors, blood products also bring along extracellular vesicles (EVs) packed with signal molecules, which open up a new level of complexity at evaluating the functional spectrum of blood products. Large proportions of EVs originated from platelets in CPRP and hypACT, whereas very low erythrocyte and monocyte-derived EVs were detected via flow cytometry. EV treatment of chondrocytes enhanced the expression of anabolic markers type II collagen, SRY-box transcription factor 9 (SOX9), and aggrecan compared to full blood products, but also the catabolic marker and tissue remodeling factor matrix metalloproteinase 3, whereas hypACT EVs prevented type I collagen expression. CPRP blood product increased SOX9 protein expression, in contrast to hypACT blood product. However, hypACT EVs induced SOX9 protein expression while preventing interleukin-6 secretion. The results indicate that blood EVs are sufficient to induce chondrogenic gene expression changes in OA chondrocytes, while preventing proinflammatory cytokine release compared to full blood product. This highlights the potential of autologous blood-derived EVs as regulators of cartilage extracellular matrix metabolism and inflammation, as well as candidates for new cell-free therapeutic approaches for OA.

show abstract

Section: Introductionmentioning

confidence: 99%

Characterization and Chondroprotective Effects of Extracellular Vesicles From Plasma- and Serum-Based Autologous Blood-Derived Products for Osteoarthritis Therapy

Otahal

Kramer

Kuten

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…Autologous blood derived products, particularly platelet concentrates, are widely applied nowadays in different regenerative therapies which include wound healing, orthopedics, and dentistry [1,2,3,4,5]. Platelet derived growth factors are able to enhance soft and hard tissue regeneration by increasing cell migration and proliferation, and decreasing the rate of inflammation [6,7].…”

Section: Introductionmentioning

confidence: 99%

The Composition of Hyperacute Serum and Platelet-Rich Plasma Is Markedly Different despite the Similar Production Method

Kardos

Simon

Vácz

et al. 2019

IJMS

View full text Add to dashboard Cite

Autologous blood derived products, such as platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) are widely applied in regenerative therapies, in contrast to the drawbacks in their application, mainly deriving from the preparation methods used. Eliminating the disadvantages of both PRP and PRF, hyperacute serum (HAS) opens a new path in autologous serum therapy showing similar or even improved regenerative potential at the same time. Despite the frequent experimental and clinical use of PRP and HAS, their protein composition has not been examined thoroughly yet. Thus, we investigated and compared the composition of HAS, serum, PRP and plasma products using citrate and EDTA by simple laboratory tests, and we compared the composition of HAS, serum, EDTA PRP and plasma by Proteome Profiler and ELISA assays. According to our results the natural ionic balance was upset in both EDTA and citrate PRP as well as in plasma. EDTA PRP contained significantly higher level of growth factors and cytokines, especially platelet derived angiogenic and inflammatory proteins, that can be explained by the significantly higher number of platelets in EDTA PRP. The composition analysis of blood derivatives revealed that although the preparation method of PRP and HAS were similar, the ionic and protein composition of HAS could be advantageous for cell function.

show abstract

“…There is a consensus in the literature that suggests that CS can reduce degenerative mechanisms and enhance tissue regeneration (Frizziero et al, 2013). Moreover, it is widely accepted that the local treatment is a safe and effective therapy (Fotouhi et al, 2018).…”

Section: Discussionmentioning

confidence: 99%

“…In a recent review from Fotouhi et al, different treatments for knee osteoarthritis were discussed from a historical perspective. The authors suggest that PRP, stromal vascular fraction, and ACS seem to have favorable and promising results (Fotouhi et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

Conditioned Serum Enhances the Chondrogenic and Immunomodulatory Behavior of Mesenchymal Stem Cells

et al. 2019

View full text Add to dashboard Cite

Osteoarthritis is one of the most common chronic health conditions associated with pain and disability. Advanced therapies based on mesenchymal stem cells have become valuable options for the treatment of these pathologies. Conditioned serum (CS, “Orthokine”) has been used intra-articularly for osteoarthritic patients. In this work, we hypothesized that the rich content on anti-inflammatory proteins and growth factors of CS may exert a beneficial effect on the biological activity of human adipose-derived mesenchymal stem cells (hAdMSCs). In vitro studies were designed using hAdMSCs cocultured with CS at different concentrations (2.5, 5, and 10%). Chondrogenic differentiation assays and immunomodulatory experiments using in vitro -stimulated lymphocytes were performed. Our results demonstrated that CS significantly enhanced the differentiation of hAdMSCs toward chondrocytes. Moreover, hAdMSCs pre-sensitized with CS reduced the lymphocyte proliferation as well as their differentiation toward activated lymphocytes. These results suggest that in vivo coadministration of CS and hAdMSCs may have a beneficial effect on the therapeutic potential of hAdMSCs. Moreover, these results indicate that intra-articular administration of CS might influence the biological behavior of resident stem cells increasing their chondrogenic differentiation and inherent immunomodulatory activity. To our knowledge, this is the first in vitro study reporting this combination.

show abstract

Platelet rich plasma, stromal vascular fraction and autologous conditioned serum in treatment of knee osteoarthritis

Cited by 61 publications

References 109 publications

Characterization and Chondroprotective Effects of Extracellular Vesicles From Plasma- and Serum-Based Autologous Blood-Derived Products for Osteoarthritis Therapy

Characterization and Chondroprotective Effects of Extracellular Vesicles From Plasma- and Serum-Based Autologous Blood-Derived Products for Osteoarthritis Therapy

The Composition of Hyperacute Serum and Platelet-Rich Plasma Is Markedly Different despite the Similar Production Method

Conditioned Serum Enhances the Chondrogenic and Immunomodulatory Behavior of Mesenchymal Stem Cells

Contact Info

Product

Resources

About